We are live on ! Find out more
UOC

UBS O'Connor Portfolio holdings

AUM $3.38B
1-Year Est. Return 63.08%
This Fund
S&P 500
This Quarter Est. Return
+12.69%
1 Year Est. Return
+63.08%
3 Year Est. Return
+180.99%
5 Year Est. Return
+483.22%
10 Year Est. Return
+2,128.59%
AUM
$3.05B
AUM Growth
-$542M
Cap. Flow
-$855M
Cap. Flow %
-28%
Top 10 Hldgs %
68.02%
Holding
472
New
104
Increased
41
Reduced
44
Closed
200

Top Buys

1
VRNA
Verona Pharma
VRNA
+$447M
2
CYBR
CyberArk
CYBR
+$424M
3
IPG
Interpublic Group of Companies
IPG
+$96.3M
4
COOP
Mr. Cooper
COOP
+$67.2M
5
AL
Air Lease Corp
AL
+$48.8M

Top Sells

1
WBA
Walgreens Boots Alliance
WBA
+$288M
2
SKX
Skechers
SKX
+$227M
3
BPMC
Blueprint Medicines
BPMC
+$220M
4
CHX
ChampionX
CHX
+$187M
5
ANSS
Ansys
ANSS
+$173M

Sector Composition

1 Technology 23.63%
2 Healthcare 16.98%
3 Communication Services 12.23%
4 Financials 11.14%
5 Consumer Staples 9.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANSS
276
DELISTED
Ansys
ANSS
– –
-492,829
Closed -$173M
ARGX icon
277
argenx
ARGX
$53.7B
– –
-2,191
Closed -$1.21M
ARVN icon
278
Arvinas
ARVN
$518M
– –
-50,000
Closed -$368K
ASML icon
279
ASML
ASML
$686B
– –
-3,000
Closed -$2.4M
ATEC icon
280
Alphatec Holdings
ATEC
$1.43B
– –
-119,094
Closed -$1.32M
AUTL
281
Autolus Therapeutics
AUTL
$389M
– –
-565,000
Closed -$1.29M
AXGN icon
282
CALL
Axogen
AXGN
$2.12B
– –
-50,000
Closed -$23.8K
AXGN icon
283
Axogen
AXGN
$2.12B
– –
-81,429
Closed -$884K
AXSM icon
284
Axsome Therapeutics
AXSM
$12.2B
– –
-6,400
Closed -$668K
AZN icon
285
AstraZeneca
AZN
$263B
– –
-21,499
Closed -$3M
BA icon
286
Boeing
BA
$169B
– –
-27,675
Closed -$5.8M
BAX icon
287
Baxter International
BAX
$12.1B
– –
-88,787
Closed -$2.69M
BBIO icon
288
BridgeBio Pharma
BBIO
$15.7B
– –
-13,771
Closed -$595K
BCYC
289
CALL
Bicycle Therapeutics
BCYC
$292M
– –
-50,000
Closed -$11.3K
BCYC
290
Bicycle Therapeutics
BCYC
$292M
– –
-143,800
Closed -$999K
BDX icon
291
Becton Dickinson
BDX
$44.1B
– –
-15,107
Closed -$2.6M
BEKE icon
292
KE Holdings
BEKE
$19.3B
– –
-51,814
Closed -$919K
BIIB icon
293
CALL
Biogen
BIIB
$30.8B
– –
-20,000
Closed -$30K
BKR icon
294
Baker Hughes
BKR
$56.1B
– –
-80,000
Closed -$3.07M
BMY icon
295
CALL
Bristol-Myers Squibb
BMY
$124B
– –
-40,000
Closed -$9K
BORR
296
CALL
Borr Drilling
BORR
$1.29B
– –
-200,000
Closed -$5K
BPMC
297
DELISTED
Blueprint Medicines
BPMC
– –
-1,713,587
Closed -$220M
BTI icon
298
British American Tobacco
BTI
$136B
– –
-82,631
Closed -$3.91M
CAPR icon
299
Capricor Therapeutics
CAPR
$1.11B
– –
-17,054
Closed -$169K
CAPR icon
300
PUT
Capricor Therapeutics
CAPR
$1.11B
– –
-33,000
Closed -$43.7K
10 11
12
13 14

Similar funds

FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
SAG
SageView Advisory Group Newport Beach, California $2.96B AUM 15.81% 1-Year Est. Return
ACI
Alpha Cubed Investments Irvine, California $2.92B AUM 31.27% 1-Year Est. Return
TCOV
Trust Company of Vermont Brattleboro, Vermont $2.4B AUM 18.8% 1-Year Est. Return
RCM
RNC Capital Management Los Angeles, California $2.2B AUM 22.93% 1-Year Est. Return
RC
RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return
A
AlphaQuest New York $1.79B AUM 10.61% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return

UBS O'Connor's Q3 2025 Portfolio in Review

As of Q3 2025, UBS O'Connor held 472 positions worth $3.05B, down 15% from $3.6B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

UBS O'Connor withdrew a net $855M in Q3 2025, closing 200 positions and reducing 44 holdings. Its most notable exit was Walgreens Boots Alliance, an estimated $288M position sold in full.

By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 15% a quarter earlier, followed by Healthcare and Communication Services.

Against the trend, UBS O'Connor opened a new position in Verona Pharma worth $457M.

  • UBS O'Connor's largest Q3 2025 buy was Verona Pharma: 4,283,462 shares worth $457M.
  • UBS O'Connor added most to Interpublic Group of Companies in Q3 2025, an estimated $96.3M increase.
  • UBS O'Connor's biggest Q3 2025 reduction was Kellanova, cutting an estimated $110M.
  • UBS O'Connor fully exited Walgreens Boots Alliance in Q3 2025, selling an estimated $288M.
  • UBS O'Connor's ten largest holdings make up 68% of its $3.05B portfolio in Q3 2025.
  • UBS O'Connor opened 104 new positions and closed 200 in Q3 2025.
  • UBS O'Connor's portfolio value fell 15% quarter-over-quarter to $3.05B.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.